# Agendia

Source: https://onco.cc/companies/agendia/  
OnCo record `agendia` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Dutch maker of MammaPrint, the 70-gene breast cancer test validated in the MINDACT trial.

## Summary

Spun out of the Netherlands Cancer Institute, Agendia developed MammaPrint (FDA-cleared 2007, the first cleared multigene prognostic test) and the BluePrint molecular subtyping assay, and sponsored MINDACT with the EORTC. It also runs the FLEX registry collecting whole-transcriptome data on MammaPrint patients.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Amsterdam / Irvine, CA
- Type: diagnostics
- Website: https://agendia.com

## Sources

- Official website: https://agendia.com

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [RNA sequencing & expression profiling](https://onco.cc/technologies/rna-seq/)
- drugs: [MammaPrint (70-gene signature)](https://onco.cc/drugs/mammaprint/)
- trials: [MINDACT](https://onco.cc/trials/mindact/)

---
JSON: https://onco.cc/api/v1/entities/agendia.json